HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer

HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer

Triple negative breast cancer (TNBC) is an urgent as well as huge medical challenge, which is associated with poor prognosis and responsiveness to chemotherapies. Since epigenetic changes are highly implicated in TNBC tumorigenesis and development, inhibitors of histone deacetylases (HDACIs) could r...

Full description

Bibliographic Details
Main Authors:	Cristina Maccallini, Alessandra Ammazzalorso, Barbara De Filippis, Marialuigia Fantacuzzi, Letizia Giampietro, Rosa Amoroso
Format:	Article
Language:	English
Published:	MDPI AG 2022-05-01
Series:	Pharmaceuticals
Subjects:	anticancer benzamide chimeric compounds hydroxamate histone deacetylase inhibitor
Online Access:	https://www.mdpi.com/1424-8247/15/6/667

Similar Items

The Importance of the “Time Factor” for the Evaluation of Inhibition Mechanisms: The Case of Selected HDAC6 Inhibitors
by: Edoardo Cellupica, et al.
Published: (2023-07-01)

Opportunities and Difficulties in the Repurposing of HDAC Inhibitors as Antiparasitic Agents
by: Tapas Kumar Mohapatra, et al.
Published: (2024-01-01)

Thiết kế, tổng hợp và đánh giá khả năng ức chế enzyme histone deacetylase (HDAC) in silico của một số dẫn xuất tương tự belinostat
by: Nguyễn Cường Quốc, et al.
Published: (2020-06-01)

Improved HDAC Inhibition, Stronger Cytotoxic Effect and Higher Selectivity against Leukemias and Lymphomas of Novel, Tricyclic Vorinostat Analogues
by: Bartosz Bieszczad, et al.
Published: (2021-08-01)

Design, synthesis and biological evaluation of novel histone deacetylase inhibitors based on virtual screening
by: Hui Lu, et al.
Published: (2011-12-01)

A Novel Hydroxamic Acid-Based Curcumin Derivative as Potent Histone Deacetylase Inhibitor for the Treatment of Glioblastoma
by: Hao Wang, et al.
Published: (2021-11-01)

Anticancer Activity and Mechanisms of Action of New Chimeric EGFR/HDAC-Inhibitors
by: Nils Goehringer, et al.
Published: (2021-08-01)

Syntheses and Biological Activity of the HDAC Class I Inhibitor Largazole
by: Tobias Seiser, et al.
Published: (2009-02-01)

Hydroxamic acid - A novel molecule for anticancer therapy
by: Dilipkumar Pal, et al.
Published: (2012-01-01)

Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
by: Marinella Zilli, et al.
Published: (2013-07-01)

Bifunctional HDAC Therapeutics: One Drug to Rule Them All?
by: Joshua P. Smalley, et al.
Published: (2020-09-01)

The Role of HDACs as Leukemia Therapy Targets using HDI
by: Ahmad Ahmadzadeh, et al.
Published: (2016-02-01)

Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases
by: Anton Frühauf, et al.
Published: (2021-08-01)

Hydroxamic Acid as a Potent Metal-Binding Group for Inhibiting Tyrosinase
by: Joonhyeok Choi, et al.
Published: (2022-01-01)

Exploration of novel 5′(7′)-substituted-2′-
by: Do Thi Mai Dung, et al.
Published: (2017-05-01)

Target Design of Novel Histone Deacetylase 6 Selective Inhibitors with 2-Mercaptoquinazolinone as the Cap Moiety
by: Hue Thi Buu Bui, et al.
Published: (2022-03-01)

Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives
by: Robert Jenke, et al.
Published: (2021-02-01)

Discovery of 1-Benzhydryl-Piperazine-Based HDAC Inhibitors with Anti-Breast Cancer Activity: Synthesis, Molecular Modeling, In Vitro and In Vivo Biological Evaluation
by: Dusan Ruzic, et al.
Published: (2022-11-01)

Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy
by: Donglu Wu, et al.
Published: (2020-11-01)

Discovery of indole-3-butyric acid derivatives as potent histone deacetylase inhibitors
by: Yiming Chen, et al.
Published: (2021-01-01)

Vorinostat (SAHA) and Breast Cancer: An Overview
by: Anna Wawruszak, et al.
Published: (2021-09-01)

Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective
by: Jacob King, et al.
Published: (2021-11-01)

Histone Deacetylase Inhibitor SAHA Improves High Salinity Tolerance Associated with Hyperacetylation-Enhancing Expression of Ion Homeostasis-Related Genes in Cotton
by: Shibin He, et al.
Published: (2020-09-01)

Correlation Analysis of Protein Expression of 10 HDAC/Sirtuin Isoenzymes with Sensitivities of 23 Anticancer Drugs in 17 Cancer Cell Lines and Potentiation of Drug Activity by Co-Treatment with HDAC Inhibitors
by: Steven Behnisch-Cornwell, et al.
Published: (2021-12-01)

Oxazole-Bridged Combretastatin A-4 Derivatives with Tethered Hydroxamic Acids: Structure–Activity Relations of New Inhibitors of HDAC and/or Tubulin Function
by: Florian Schmitt, et al.
Published: (2019-01-01)

In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model
by: Thiemann Markus, et al.
Published: (2012-03-01)

Current HDAC Inhibitors in Clinical Trials
by: Elisabetta Di Bello, et al.
Published: (2022-05-01)

Discovery of potent histone deacetylase inhibitors with modified phenanthridine caps
by: Wenli Fan, et al.
Published: (2021-01-01)

Improved Anticancer Activities of a New Pentafluorothio-Substituted Vorinostat-Type Histone Deacetylase Inhibitor
by: Nils Goehringer, et al.
Published: (2021-12-01)

Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis
by: Stephen G. Smoots, et al.
Published: (2024-03-01)

Synthesis, Antiplasmodial, and Antileukemia Activity of Dihydroartemisinin–HDAC Inhibitor Hybrids as Multitarget Drugs
by: Lukas von Bredow, et al.
Published: (2022-03-01)

HDAC Inhibitors Enhance Efficacy of the Oncolytic Adenoviruses Ad∆∆ and Ad-3∆-A20T in Pancreatic and Triple-Negative Breast Cancer Models
by: María Del Carmen Rodríguez Rodríguez, et al.
Published: (2022-05-01)

Effects of novel HDAC inhibitors on urothelial carcinoma cells
by: Aline Kaletsch, et al.
Published: (2018-07-01)

Discovery of novel polysubstituted N-alkyl acridone analogues as histone deacetylase isoform-selective inhibitors for cancer therapy
by: Ze Wang, et al.
Published: (2023-12-01)

HAT- and HDAC-Targeted Protein Acetylation in the Occurrence and Treatment of Epilepsy
by: Jie Wang, et al.
Published: (2022-12-01)

Histone Deacetylase Inhibitors from Marine Invertebrates
by: Claudio Luparello, et al.
Published: (2020-11-01)

Preclinical Studies in the mdx Mouse Model of Duchenne Muscular Dystrophy with the Histone Deacetylase Inhibitor Givinostat
by: Silvia Consalvi, et al.
Published: (2013-03-01)

The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus
by: Saikat Dewanjee, et al.
Published: (2021-05-01)

Inhibiting Histone Deacetylase 2 (HDAC2) Promotes Functional Recovery From Stroke
by: Ying Tang, et al.
Published: (2017-10-01)

HDAC3 and HDAC8 are required for cilia assembly and elongation
by: Seon-ah Park, et al.
Published: (2019-08-01)